

China Cord Blood Corporation to Change Corporate Name to “Global Cord Blood Corporation”

Extraordinary Meeting of Shareholders to be Held to Approve Change

HONG KONG, China, February 7, 2018 -- China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), leading cord blood banking operator in China, today announced that the Board of Directors of the Company (the “Board”) has approved seeking shareholder approval regarding the change of the Company’s name from “China Cord Blood Corporation” to “Global Cord Blood Corporation” (“Change of Name”). The Board believes that the Change of Name better reflects the future development direction and business strategy of the Company. The Company plans to hold an extraordinary general meeting (“EGM”) for shareholders to approve the Change of Name at its Hong Kong office at 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, at 8:00 p.m. Hong Kong Time on March 16, 2018 (8:00 a.m. U.S. Eastern Daylight Time on March 16, 2018).

Shareholders of record as of February 27, 2018 will be entitled to receive notice of and vote at the EGM. Shareholders may request a meeting notice, proxy statement free of charge by contacting ir@chinacordbloodcorp.com.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and no new licenses will be granted before 2020 in addition to the seven licenses authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at <http://www.chinacordbloodcorp.com>.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the U.S. Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.



中國臍帶血庫企業集團

China Cord Blood Corporation

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com

ICR, Inc.
William Zima
Tel: (+86) 10-6583-7511 (China) or (+1) 646-405-5185 (U.S.)
Email: william.zima@icrinc.com